Skip to content
DataLookout
Menu

ES-ERCPNCT07702240

Esketamine Versus Sufentanil for Sedation in Patients Undergoing ERCP

StatusNot Yet Recruiting
PhasePhase 4
SponsorRen Da
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Not applicable → Phase 4 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Start date: Jul 10, 2026 to Nov 11, 2026
    • Eligibility criteria expanded, about 163 words
    • Enrollment target: 530 to 580
    • Secondary endpoint revised
    • Study description expanded, about 36 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage of Participants With Hypoxemia at Each Assessment Time Point
Timeframe: Baseline, and during procedure: T0 (end of induction), T1 (endoscope insertion), T2 (papillary intervention), T3 (end of procedure), and T4 (eye opening)

Secondary (1)

Percentage of Participants With Hypotension at Each Assessment Time Point

Arms and interventions

Esketamine armExperimental

Participants receive intravenous esketamine in combination with propofol for procedural sedation during ERCP. Esketamine is administered as an adjunct analgesic during induction of sedation, while propofol is continuously infused and titrated according to clinical sedation requirements.

Sufentanil armActive comparator

Participants receive intravenous sufentanil in combination with propofol for procedural sedation during ERCP. Sufentanil is administered as an adjunct analgesic during induction of sedation, while propofol is continuously infused and titrated according to clinical sedation requirements.

Drugs: Esketamine, Sufentanil